AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28187226 — intervention group
Group type: COMPARATOR
Intervention: Calcifediol (25D3)
Number of subjects: 35
Study 28187226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (D3)
Number of subjects: 35
Study 28187226 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 35
Study 25584475 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced training in Motivational Interviewing through an online learning community
Number of subjects: 0
Study 25584475 — intervention group
Group type: COMPARATOR
Intervention: Training as usual
Number of subjects: 0
Study 25584475 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample (both groups)
Number of subjects: 0
Study 25399616 — intervention group
Group type: EXPERIMENTAL
Intervention: AEC/soap-based cleanser
Number of subjects: 30
Study 25399616 — intervention group
Group type: COMPARATOR
Intervention: Usual facial cleanser
Number of subjects: 30
Study 21755327 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA‐enriched tomato juice (500 mL daily, providing 250 mg of EPA and DHA)
Number of subjects: 18
Study 21755327 — intervention group
Group type: EXPERIMENTAL
Intervention: n‐3 PUFA‐enriched tomato juice
Number of subjects: 18
Study 21755327 — intervention group
Group type: COMPARATOR
Intervention: plain tomato juice
Number of subjects: 18
Study 19663689 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine plus lopinavir-ritonavir (n = 34)
Number of subjects: 67
Study 19663689 — intervention group
Group type: COMPARATOR
Intervention: Control group (lopinavir-ritonavir plus 2 NRTIs; n = 33)
Number of subjects: 67
Study 17582564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a live oral typhoid vaccine (2 doses in Norte, 3 doses in Occidente)
Number of subjects: 0
Study 17582564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ty21a live oral typhoid vaccine (pooled analysis)
Number of subjects: 0
Study 15271236 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular cooling device
Number of subjects: 153
Study 15271236 — intervention group
Group type: COMPARATOR
Intervention: Surface convective air blanket
Number of subjects: 153
Study 11588454 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg iv omeprazole bolus injection (arm I)
Number of subjects: 10
Study 11588454 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg bolus followed by 8 mg/hr continuous infusion (arm II)
Number of subjects: 10
Study 9337181 — intervention group
Group type: EXPERIMENTAL
Intervention: gemfibrozil 1200 mg/d
Number of subjects: 395
Study 9337181 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 395
Study 7902479 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 383
Study 7902479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 383
Study 3510839 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline lavage
Number of subjects: 159
Study 3510839 — intervention group
Group type: COMPARATOR
Intervention: Saline lavage
Number of subjects: 159
Study 31693299 — intervention group
Group type: EXPERIMENTAL
Intervention: Differential fractional excretion of sodium (FeNa) derived from a morning void collection
Number of subjects: 139
Study 31693299 — intervention group
Group type: EXPERIMENTAL
Intervention: INTERSALT equation
Number of subjects: 139
Study 29407520 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration (WBV)
Number of subjects: 20
Study 29407520 — intervention group
Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 20
Study 27584715 — intervention group
Group type: EXPERIMENTAL
Intervention: Matrix therapy agent (ReGeneraTing Agent [RGTA])
Number of subjects: 40
Study 27584715 — intervention group
Group type: COMPARATOR
Intervention: Hyaluronic acid‐containing eyedrops, 0.1%
Number of subjects: 40
Study 23954039 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPES (Helping Older People Experience Success) intervention
Number of subjects: 183
Study 23954039 — intervention group
Group type: COMPARATOR
Intervention: TAU (Treatment as Usual)
Number of subjects: 183
Study 21652150 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal spray of oxytocin
Number of subjects: 40
Study 21652150 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20172127 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) pretreatment for 30 minutes each day for five consecutive days before surgery.
Number of subjects: 60
Study 20172127 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) pretreatment
Number of subjects: 60
Study 20172127 — intervention group
Group type: COMPARATOR
Intervention: Control group (no EA pretreatment)
Number of subjects: 60
Study 18271430 — intervention group
Group type: EXPERIMENTAL
Intervention: Home blood pressure monitor (HBPM) plus usual care
Number of subjects: 34
Study 18271430 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 34
Study 16245966 — intervention group
Group type: EXPERIMENTAL
Intervention: Brinzolamide twice-daily
Number of subjects: 58
Study 16245966 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide three times daily (Control)
Number of subjects: 58
Study 12076696 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole 50 mg once daily for 7-14 days
Number of subjects: 243
Study 12076696 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B 0.5 g thrice daily for 7-14 days
Number of subjects: 243
Study 9527195 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of 30 g alpha‐KG/hour after the operation
Number of subjects: 22
Study 9527195 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 22
Study 7608318 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 10 mg
Number of subjects: 8
Study 7608318 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 20 mg
Number of subjects: 8
Study 7608318 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptastigmine 30 mg
Number of subjects: 8
Study 7608318 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 2187791 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphaphenazole 1 g 12 hourly by mouth x 10 days
Number of subjects: 136
Study 2187791 — intervention group
Group type: EXPERIMENTAL
Intervention: Inj streptomycin 1 g intramuscularly daily with sulphaphenazole 1 g 12 hourly orally x 10 days
Number of subjects: 136
Study 2187791 — intervention group
Group type: EXPERIMENTAL
Intervention: trimethoprim 200 mg 12 hourly by mouth x 7‐10 days
Number of subjects: 136
Study 2187791 — intervention group
Group type: EXPERIMENTAL
Intervention: erythromycin 500 mg 6 hourly orally x 7‐10 days
Number of subjects: 136
Study 7031187 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg)
Number of subjects: 23
Study 7031187 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 mg)
Number of subjects: 23
Study 7031187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 30813125 — intervention group
Group type: EXPERIMENTAL
Intervention: Device-guided rehabilitation combined with traditional techniques
Number of subjects: 67
Study 30813125 — intervention group
Group type: COMPARATOR
Intervention: Conventional pulmonary rehabilitation treatments (pursed lips breathing and abdominal breathing training)
Number of subjects: 67
Study 28187506 — intervention group
Group type: EXPERIMENTAL
Intervention: Efavirenz
Number of subjects: 0
Study 28187506 — intervention group
Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 0
Study 28187506 — intervention group
Group type: COMPARATOR
Intervention: Control (ART-naïve women)
Number of subjects: 0
Study 26125924 — intervention group
Group type: EXPERIMENTAL
Intervention: Early enteral nutrition (EEN) in water during early postoperative period
Number of subjects: 300
Study 26125924 — intervention group
Group type: COMPARATOR
Intervention: Conventional perioperative treatment
Number of subjects: 300
Study 23414174 — intervention group
Group type: EXPERIMENTAL
Intervention: Personal Concerns Inventory plus treatment as usual
Number of subjects: 76
Study 23414174 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual only
Number of subjects: 76
Study 21717884 — intervention group
Group type: EXPERIMENTAL
Intervention: Travoprost 0.004%/Timolol 0.5% fixed combination
Number of subjects: 32
Study 21717884 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005%/Timolol 0.5% fixed combination
Number of subjects: 32
Study 21717884 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% twice a day
Number of subjects: 32
Study 19366826 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab (Erbitux) in monotherapy or in combination with irinotecan
Number of subjects: 200
Study 17190733 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium antagonist (Ca-A)
Number of subjects: 2729
Study 17190733 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I)
Number of subjects: 2729
Study 17190733 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II receptor antagonist (ARB)
Number of subjects: 2729
Study 17190733 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive BP-lowering group
Number of subjects: 2729
Study 17190733 — intervention group
Group type: EXPERIMENTAL
Intervention: Less intensive BP-lowering group
Number of subjects: 2729
Study 15014018 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose IFN-alpha 2b (HDI)
Number of subjects: 2000
Study 15014018 — intervention group
Group type: COMPARATOR
Intervention: Observation (Obs)
Number of subjects: 2000
Study 11245347 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination vaccine
Number of subjects: 158
Study 11245347 — intervention group
Group type: COMPARATOR
Intervention: Associated administration
Number of subjects: 158
Study 9758295 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid magnesium (CSF Mg+2) levels
Number of subjects: 96
Study 9758295 — intervention group
Group type: COMPARATOR
Intervention: Serum magnesium (serum Mg+2) levels
Number of subjects: 96
Study 7805677 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 W to 40 W step increase
Number of subjects: 9
Study 7805677 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 W to 80 W step increase
Number of subjects: 9
Study 7805677 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactic acid concentration during ramp tests at exercise intensities > 160 W in supine position
Number of subjects: 9
Study 7805677 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean power at 4 mmol.l-1 [la-]b
Number of subjects: 9
Study 7805677 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal oxygen uptake relative to body mass
Number of subjects: 9
Study 2647819 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol aerosol (180 micrograms, four times a day)
Number of subjects: 204
Study 2647819 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol powder (200 micrograms, four times a day)
Number of subjects: 204
Study 31515190 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB (group B, n = 40)
Number of subjects: 80
Study 31515190 — intervention group
Group type: COMPARATOR
Intervention: Control (group C, n = 40)
Number of subjects: 80
Study 31512815 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (CoQ10) supplementation for 24 weeks
Number of subjects: 0
Study 31512815 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 28108189 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored Internet‐based safety decision aid
Number of subjects: 720
Study 28108189 — intervention group
Group type: COMPARATOR
Intervention: Control website (typical safety information available online)
Number of subjects: 720
Study 26467414 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive omega-3 fatty acid supplementation
Number of subjects: 0
Study 26467414 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive omega-3 fatty acids
Number of subjects: 0
Study 26467414 — intervention group
Group type: COMPARATOR
Intervention: Omega-3 supplementation
Number of subjects: 0
Study 23174499 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief dynamic therapy (BDT)
Number of subjects: 88
Study 23174499 — intervention group
Group type: COMPARATOR
Intervention: Brief supportive psychotherapy (BSP)
Number of subjects: 88
Study 21932934 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser (810 nm)
Number of subjects: 40
Study 21932934 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense pulsed light (IPL)
Number of subjects: 40
Study 21932934 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of IPL and radio frequency (RF)
Number of subjects: 40
Study 21932934 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated square)
Number of subjects: 40
Study 21932934 — intervention group
Group type: EXPERIMENTAL
Intervention: Diode laser
Number of subjects: 40
Study 21932934 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL
Number of subjects: 40
Study 21932934 — intervention group
Group type: EXPERIMENTAL
Intervention: IPL+RF
Number of subjects: 40
Study 18242894 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical DHEA (1%)
Number of subjects: 20
Study 18242894 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (Control)
Number of subjects: 20
Study 16490538 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 14640494 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus chloroquine
Number of subjects: 175
Study 14640494 — intervention group
Group type: EXPERIMENTAL
Intervention: SP plus paracetamol
Number of subjects: 175
Study 14640494 — intervention group
Group type: COMPARATOR
Intervention: SP alone
Number of subjects: 175
Study 14640494 — intervention group
Group type: COMPARATOR
Intervention: Chloroquine alone
Number of subjects: 175
Study 14640494 — intervention group
Group type: EXPERIMENTAL
Intervention: All SP-treated groups
Number of subjects: 175
Study 14640494 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 175
Study 10971385 — intervention group
Group type: EXPERIMENTAL
Intervention: Amifostine (740 mg/m2)
Number of subjects: 68
Study 10971385 — intervention group
Group type: COMPARATOR
Intervention: Control (no amifostine)
Number of subjects: 68
Study 8855148 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisphosphonate treatment (various doses)
Number of subjects: 177
Study 8855148 — intervention group
Group type: EXPERIMENTAL
Intervention: RIA (gamma)
Number of subjects: 177
Study 8855148 — intervention group
Group type: EXPERIMENTAL
Intervention: Postmenopausal women
Number of subjects: 177
Study 8855148 — intervention group
Group type: COMPARATOR
Intervention: Premenopausal women
Number of subjects: 177
Study 1610422 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine
Number of subjects: 9
Study 1610422 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg ranitidine
Number of subjects: 9
Study 1610422 — intervention group
Group type: COMPARATOR
Intervention: pentagastrin (0.37 microgram/kg, 0.75 microgram/kg, 1.5 micrograms/kg)
Number of subjects: 9
Study 6091521 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular Prolene
Number of subjects: 102
Study 6091521 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcuticular Dexon
Number of subjects: 102
Study 6091521 — intervention group
Group type: EXPERIMENTAL
Intervention: Op‐Site wound closure adhesive membrane
Number of subjects: 102
Study 30736030 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraneural sensory feedback
Number of subjects: 1
Study 29345848 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 147
Study 29345848 — intervention group
Group type: COMPARATOR
Intervention: Therapist Guided Internet-based Self-help (GSH-I)
Number of subjects: 147
Study 27521354 — intervention group
Group type: EXPERIMENTAL
Intervention: Wheeled knee walker
Number of subjects: 24
Study 27521354 — intervention group
Group type: COMPARATOR
Intervention: Axillary crutches
Number of subjects: 24
Study 24345793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (300 μg/d)
Number of subjects: 62
Study 24345793 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study 24345793 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (for women)
Number of subjects: 62
Study 22752591 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported questionnaire items
Number of subjects: 0
Study 22752591 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster of three self-reported items (distribution of pain below the knee, leg pain worse than back pain, feeling of numbness or pins and needles in the leg)
Number of subjects: 0
Study 22752591 — intervention group
Group type: COMPARATOR
Intervention: Clinical assessment
Number of subjects: 0
Study 20633307 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 18595436 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (600 mg for 5 days)
Number of subjects: 10
Study 16199843 — intervention group
Group type: EXPERIMENTAL
Intervention: Supported employment program
Number of subjects: 1273
Study 16199843 — intervention group
Group type: COMPARATOR
Intervention: Comparison/services-as-usual condition
Number of subjects: 1273
Study 11863118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide 50 mg/m2 for 21 consecutive days every 4 weeks for three courses
Number of subjects: 144
Study 11863118 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (observation)
Number of subjects: 144
Study 11863118 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral etoposide
Number of subjects: 144
Study 10080231 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotic drugs (AP)
Number of subjects: 45
Study 10080231 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 8567835 — intervention group
Group type: EXPERIMENTAL
Intervention: Gamete intra-Fallopian transfer (GIFT)
Number of subjects: 69
Study 8567835 — intervention group
Group type: COMPARATOR
Intervention: In-vitro fertilization (IVF) and embryo transfer
Number of subjects: 69
Study 2076391 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg nifedipine/day
Number of subjects: 0
Study 2076391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7030354 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA (12 tablets, 3 g daily for 8 weeks)
Number of subjects: 432
Study 7030354 — intervention group
Group type: COMPARATOR
Intervention: Pyrithioxine (3 tablets, 600 mg daily for 8 weeks)
Number of subjects: 432
Study 7030354 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 432
Study 7030354 — intervention group
Group type: EXPERIMENTAL
Intervention: GABA
Number of subjects: 432
Study 7030354 — intervention group
Group type: COMPARATOR
Intervention: Pyrithioxine
Number of subjects: 432
Study 30761961 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole grain diet (120 g of bread made with whole flour daily)
Number of subjects: 100
Study 30761961 — intervention group
Group type: COMPARATOR
Intervention: Regular consumption of refined grains (control group)
Number of subjects: 100
Study 27684354 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-pharmacist collaborative intervention
Number of subjects: 399
Study 27684354 — intervention group
Group type: COMPARATOR
Intervention: Usual care (physician management alone)
Number of subjects: 399
Study 25529309 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended haemodialysis (≥24 h weekly)
Number of subjects: 200
Study 25529309 — intervention group
Group type: COMPARATOR
Intervention: Standard haemodialysis (12-18 h weekly)
Number of subjects: 200
Study 23243242 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diets with lower valine-to-lysine ratio
Number of subjects: 200
Study 23243242 — intervention group
Group type: EXPERIMENTAL
Intervention: Test diets with higher valine-to-lysine ratio
Number of subjects: 200
Study 23243242 — intervention group
Group type: COMPARATOR
Intervention: Control diet with 100% recommended lysine and adequate Val/Lys ratio
Number of subjects: 200
Study 22143010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 μg and propofol 0.5 mg/kg (group P)
Number of subjects: 46
Study 22143010 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl 50 μg and etomidate 0.1 mg/kg (group E)
Number of subjects: 46
Study 18845657 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education program (4-hour group session)
Number of subjects: 150
Study 18845657 — intervention group
Group type: COMPARATOR
Intervention: Standard information leaflet (control group)
Number of subjects: 150
Study 17182429 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengths Oriented Family Therapy (SOFT)
Number of subjects: 0
Study 17182429 — intervention group
Group type: EXPERIMENTAL
Intervention: The Seven Challenges (7C)
Number of subjects: 0
Study 12625645 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuronal transplantation
Number of subjects: 0
Study 10842106 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid fixation (n = 64) with three 2‐mm bicortical position screws bilaterally and elastics.
Number of subjects: 127
Study 10842106 — intervention group
Group type: COMPARATOR
Intervention: Wire fixation (n = 63) with inferior border wires and 6 weeks of skeletal maxillomandibular fixation with 24‐gauge wires.
Number of subjects: 127
Study 10842106 — intervention group
Group type: COMPARATOR
Intervention: Both groups (Rigid and Wire)
Number of subjects: 127
Study 9041856 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.01% tropicamide
Number of subjects: 40
Study 9041856 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 8370866 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term psychological treatments
Number of subjects: 75
Study 8370866 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive view of bulimia nervosa
Number of subjects: 75
Study 3534584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 170
Study 3534584 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 29533038 — intervention group
Group type: EXPERIMENTAL
Intervention: Arthroscopy-guided core decompression and bone grafting combined with selective arterial infusion
Number of subjects: 76
Study 29533038 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous core decompression combined with selective arterial infusion
Number of subjects: 76